Skip to main content
AAN.com

Abstract

Background and Objectives

Studies of association between air pollution and incidence of dementia have shown discrepant results. The aim of this study was to evaluate the association between air pollution and dementia.

Methods

In this systematic review and meta-analysis, PubMed, MEDLINE, EMBASE, PsycINFO, Scopus, and Web of Science were searched and updated in August 2021. Population-based cohort studies that reported on hazard ratio (HR) of dementia in association with exposure to fine particulate matter (PM2·5), nitrogen oxides (NOX), nitrogen dioxide (NO2), or ozone (O3) in those aged >40 years were included. Data were extracted by 2 independent investigators. The main outcome was the pooled HR for dementia per increment of pollutant, calculated using a random-effects model. Results were reported in accordance with PRISMA guidelines. The protocol was registered in PROSPERO (registration number: CRD42020219036).

Results

A total of 20 studies were included in the systematic review, and 17 provided data for the meta-analysis. The total included population was 91,391,296, with 5,521,111 (6%) being diagnosed with dementia. A total of 12, 5, 6, and 4 studies were included in the meta-analyses of PM2·5, NOX, NO2, and O3, respectively. The risk of dementia increased by 3% per 1 μg/m3 increment in PM2·5 (HR, 1.03; 95% CI [1.02–1.05]; I2 = 100%). The association between dementia per 10 μg/m3 increment in NOX (HR, 1.05; 95% CI [0.99–1.13]; I2 = 61%), NO2 (HR, 1.03; 95% CI [1.00–1.07]; I2 = 94%), and O3 levels (HR, 1.01; 95% CI [0.91–1.11]; I2 = 82%) was less clear, although a significant association could not be ruled out, and there was high heterogeneity across studies.

Discussion

Existing evidence suggests a significant association between exposure to PM2·5 and incidence of dementia and nonsignificant association between dementia and NOX, NO2, and O3 exposure. However, results should be interpreted in light of the small number of studies and high heterogeneity of effects across studies.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Hurd MD, Martorell P, Langa KM, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;369(5):489-490.
2.
Prince M, Guerchet M, Prina M. Policy Brief for Heads of Government: The Global Impact of Dementia 2013-20502013.
3.
Organization WH. Dementia: A Public Health Priority. World Health Organization; 2012.
4.
World Health Organization: “Ambient (Outdoor) Air Quality and health.” [online]. who.int/mediacentre/factsheets/fs313/en/
5.
CLARITY Group MU. Tool to Assess Risk of Bias in Cohort Studies [online]. evidencepartners.com/wp-content/uploads/2017/09/Tool-to-Assess-Risk-of-Bias-in-Cohort-Studies.pdf
6.
Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114-124.
7.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
8.
Andersson J, Oudin A, Sundström A, Forsberg B, Adolfsson R, Nordin M. Road traffic noise, air pollution, and risk of dementia - results from the Betula project. Environ Res. 2018;166:334-339.
9.
Cacciottolo M, Wang X, Driscoll I, et al. Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. Transl Psychiatry. 2017;7(1):e1022.
10.
Carey IM, Anderson HR, Atkinson RW, et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open. 2018;8(9):e022404.
11.
Cerza F, Renzi M, Gariazzo C, et al. Long-term exposure to air pollution and hospitalization for dementia in the Rome longitudinal study. Environ Health. 2019;18(1):72-72.
12.
Chang KH, Chang MY, Muo CH, Wu TN, Chen CY, Kao CH. Increased risk of dementia in patients exposed to nitrogen dioxide and carbon monoxide: a population-based retrospective cohort study. PLoS One. 2014;9(8):e103078.
13.
Chen H, Kwong JC, Copes R, et al. Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int. 2017;108:271-277.
14.
Grande G, Ljungman PLS, Eneroth K, Bellander T, Rizzuto D. Association between cardiovascular disease and long-term exposure to air pollution with the risk of dementia. JAMA Neurol. 2020;77(7):801-809.
15.
Ilango SD, Chen H, Hystad P, et al. The role of cardiovascular disease in the relationship between air pollution and incident dementia: a population-based cohort study. Int J Epidemiol. 2020;49(1):36-44.
16.
Jung CR, Lin YT, Hwang BF. Ozone, particulate matter, and newly diagnosed Alzheimer's disease: a population-based cohort study in Taiwan. J Alzheimer's Dis. 20152015;44(2):573-584.
17.
Kioumourtzoglou MA, Schwartz JD, Weisskopf MG, et al. Long-term PM2.5 exposure and neurological hospital admissions in the Northeastern United States. Environ Health Perspect. 2016;124(1):23-29.
18.
Lee M, Schwartz J, Wang Y, Dominici F, Zanobetti A. Long-term effect of fine particulate matter on hospitalization with dementia. Environ Pollut. 2019;254(Pt A):112926-112926.
19.
Mortamais M, Gutierrez LA, de Hoogh K, et al. Long-term exposure to ambient air pollution and risk of dementia: results of the prospective Three-City Study. Environ Int. 2021;148:106376.
20.
Oudin A, Forsberg B, Adolfsson AN, et al. Traffic-related air pollution and dementia incidence in northern Sweden: a longitudinal study. Environ Health Perspect. 2016;124(3):306-312.
21.
Oudin A, Segersson D, Adolfsson R, Forsberg B. Association between air pollution from residential wood burning and dementia incidence in a longitudinal study in Northern Sweden. PLoS One. 2018;13(6):e0198283.
22.
Oudin A, Andersson J, Sundstrom A, et al. Traffic-related air pollution as a risk factor for dementia: No clear modifying effects of APOEɛ4 in the Betula cohort. J Alzheimer's Dis. 2019;71(3):733-740.
23.
Paul KC, Haan M, Yu Y, et al. Traffic-related air pollution and incident dementia: direct and indirect pathways through metabolic dysfunction. J Alzheimers Dis. 2020;76(4):1477-1491.
24.
Ran J, Schooling CM, Han L, et al. Long-term exposure to fine particulate matter and dementia incidence: a cohort study in Hong Kong. Environ Pollut. 2021;271:116303.
25.
Shi L, Wu X, Danesh Yazdi M, et al. Long-term effects of PM(2·5) on neurological disorders in the American Medicare population: a longitudinal cohort study. Lancet Planet Health. 2020;4(12):e557–e565.
26.
Smargiassi A, Sidi EAL, Robert LE, et al. Exposure to ambient air pollutants and the onset of dementia in Québec, Canada. Environ Res. 2020;190:109870.
27.
Yuchi W, Sbihi H, Davies H, Tamburic L, Brauer M. Road proximity, air pollution, noise, green space and neurologic disease incidence: a population-based cohort study. Environ Health. 2020;19(1):8-8.
28.
Tsai TL, Lin YT, Hwang BF, et al. Fine particulate matter is a potential determinant of Alzheimer's disease: a systemic review and meta-analysis. Environ Res. 2019;177:108638.
29.
Fu P, Guo X, Cheung FMH, Yung KKL. The association between PM(2.5) exposure and neurological disorders: a systematic review and meta-analysis. Sci Total Environ. 2019;655:1240-1248.
30.
Fu P, Yung KKL. Air pollution and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2020;77(2):701-714.
31.
Calderon-Garciduenas L, Reed W, Maronpot RR, et al. Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. Toxicol Pathol. 2004;32(6):650-658.
32.
Calderon-Garciduenas L, Solt AC, Henriquez-Roldan C, et al. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. Toxicol Pathol. 2008;36(2):289-310.
33.
Calderon-Garciduenas L, Engle R, Mora-Tiscareno A, et al. Exposure to severe urban air pollution influences cognitive outcomes, brain volume and systemic inflammation in clinically healthy children. Brain Cogn. 2011;77(3):345-355.
34.
Liu L, Urch B, Szyszkowicz M, et al. Influence of exposure to coarse, fine and ultrafine urban particulate matter and their biological constituents on neural biomarkers in a randomized controlled crossover study. Environ Int. 2017;101:89-95.
35.
COMEAP. The Effects of Long-Term Exposure to Ambient Air Pollution on Cardiovascular Morbidity: Mechanistic Evidence A Report by the Committee on the Medical Effects of Air Pollutants. [online]. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/749657/COMEAP_CV_Mechanisms_Report.pdf. Accessed Sep 9, 2021.
36.
Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement. 2018;14(2):148-156.
37.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.
38.
Valavanidis A, Fiotakis K, Vlachogianni T. Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2008;26(4):339-362.
39.
Adams K, Greenbaum DS, Shaikh R, van Erp AM, Russell AG. Particulate matter components, sources, and health: systematic approaches to testing effects. J Air Waste Manage Assoc. 19952015;65(5):544-558.
Letters to the Editor
25 January 2023
Reader Response: Air Pollution and Incidence of Dementia: A Systematic Review and Meta-analysis
Tomoyuki Kawada, Professor| Nippon Medical School

Abolhasani et al. conducted a meta-analysis to evaluate the association between air pollution and incidence of dementia.1 Pooled hazard ratio (HR) (95% confidence interval [CI]) of particulate matter with an aerodynamic diameter less than 2·5 μm (PM2·5) with 10 μg/m3 increment for the risk of dementia was 1.03 (1.02-1.05). In contrast, there were no significant associations of dementia incidence with nitrogen oxides, nitrogen dioxide, or ozone. The authors recommended further studies to keep enough number of studies for stable estimates. There are additional studies related to types of dementia and indicators of air pollution.

Cheng et al. also conducted a meta-analysis by specifying two subtypes including Alzheimer disease (AD) and vascular dementia (VaD).2 The age of the subjects was ≥40 years, which was the same age range studied by Abolhasani et al. Pooled HRs (95% CIs) of long-term exposure to PM2·5 with 10 μg/m3 increment for the risk of all-cause dementia, AD, and VaD were 1.40 (1.23-1.60), 1.47 (1.22-1.78), and 2.00 (1.30-3.08), respectively. Period and level of exposure to environmental pollutants may be difficult to determine because there are fluctuations in indoor and outdoor generation sources in each individual. In addition, time trends of exposure may also be difficult to determine by long-term monitoring. Taken together, accumulation of air pollution into the body may be difficult to estimate. It is possible that environmental monitoring data could be used as a substitute for individual exposure to air pollution.

Dhiman et al. conducted a meta-analysis by additional use of particulate matter with an aerodynamic diameter less than 10 μm, carbon monoxide, and sulfur dioxide.3 The increased risk of all-cause dementia, AD, and VaD were recognized only in PM2·5 exposure, presenting pooled HRs (95% CIs) of 1.03 (1.01-1.06), 1.08 (1.01-1.15), 1.03 (1.01-1.06), respectively. Other indicators did not present significant associations with dementia incidence. They also observed that there was a wide variation for evaluating the association between air pollution and cognitive decline. Risk assessment of dementia may be difficult, because many factors would affect cognitive performance such as hypertension, drinking, obesity, smoking, depression, social isolation, lack of exercise, air pollution and diabetes.4

There are many individual risk factors of dementia incidence, and intrinsic and extrinsic factors may interact with each other during long-term periods. Deposition of amyloid beta was closely associated with exposure to air pollution5, and APOE alleles were significant contributors for the progression of cognitive impairment.6  Air pollution may be an important risk factor for AD and other types of dementia, and appropriate indicators, such as PM2·5, should be included in the risk assessment.

References

1. Abolhasani E, Hachinski V, Ghazaleh N, et al. Air Pollution and Incidence of Dementia: A Systematic Review and Meta-analysis. Neurology 2023;100(2):e242-e254.

2. Cheng S, Jin Y, Dou Y, et al. Long-term particulate matter 2.5 exposure and dementia: a systematic review and meta-analysis. Public Health 2022;212:33-41.

3. Dhiman V, Trushna T, Raj D, et al. Is Air Pollution Associated with Increased Risk of Dementia? A Meta-Analysis of Epidemiological Research. Neurol India 2022;70(3):1004-1019.

4. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396(10248):413-446.

Author disclosures are available upon request([email protected]).

Information & Authors

Information

Published In

Neurology®
Volume 100Number 2January 10, 2023
Pages: e242-e254
PubMed: 36288998

Publication History

Received: October 5, 2021
Accepted: August 31, 2022
Published online: October 26, 2022
Published in print: January 10, 2023

Permissions

Request permissions for this article.

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Study Funding

The authors report no targeted funding.

Authors

Affiliations & Disclosures

Ehsan Abolhasani, MD, MSc https://orcid.org/0000-0002-4241-6990
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Vladimir Hachinski, MD, DSc https://orcid.org/0000-0002-0487-734X
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nargess Ghazaleh, MD, MSc
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mahmoud Reza Azarpazhooh, MD
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Naghmeh Mokhber, MD, FRCPC
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Janet Martin, PharmD, MSc (HTA) https://orcid.org/0000-0002-3599-8427
From the Department of Epidemiology and Biostatistics (E.A., V.H., M.R.A., J.M), Clinical Neurological Sciences (V.H., M.R.A.), and Neuroscience Program (N.G.), Schulich School of Medicine and Dentistry, Western University, London, ON; Department of Psychiatry (N.M.), Schulich School of Medicine and Dentistry, University of Western Ontario, London; and Department of Anesthesia and Perioperative Medicine (J.M.), MEDICI Centre, Western University, London, ON, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Martin [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Submitted and externally peer reviewed. The handling editor was Linda Hershey, MD, PhD, FAAN.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Impact of air pollution on depressive symptoms and the modifying role of physical activity: Evidence from the CHARLS study, Journal of Hazardous Materials, 482, (136507), (2025).https://doi.org/10.1016/j.jhazmat.2024.136507
    Crossref
  2. Particulate matter, socioeconomic status, and cognitive function among older adults in China, Archives of Gerontology and Geriatrics, 131, (105756), (2025).https://doi.org/10.1016/j.archger.2025.105756
    Crossref
  3. Environmental pollution and brain function, Encyclopedia of the Human Brain, (483-496), (2025).https://doi.org/10.1016/B978-0-12-820480-1.00162-5
    Crossref
  4. Wildfire Smoke Exposure and Incident Dementia, JAMA Neurology, 82, 1, (40), (2025).https://doi.org/10.1001/jamaneurol.2024.4058
    Crossref
  5. Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History, Journal of Clinical Medicine, 13, 2, (536), (2024).https://doi.org/10.3390/jcm13020536
    Crossref
  6. Particulate Matter-Induced Emerging Health Effects Associated with Oxidative Stress and Inflammation, Antioxidants, 13, 10, (1256), (2024).https://doi.org/10.3390/antiox13101256
    Crossref
  7. Progesterone Receptor Membrane Component 1 Regulates Cellular Stress Responses and Inflammatory Pathways in Chronic Neuroinflammatory Conditions, Antioxidants, 13, 2, (230), (2024).https://doi.org/10.3390/antiox13020230
    Crossref
  8. Comparison of regional vs. general anesthesia on the risk of dementia: a systematic review and meta-analysis, Frontiers in Public Health, 12, (2024).https://doi.org/10.3389/fpubh.2024.1362461
    Crossref
  9. Air pollution exposure and inflammatory bowel disease: a systematic literature review of epidemiological and mechanistic studies, Frontiers in Environmental Health, 3, (2024).https://doi.org/10.3389/fenvh.2024.1463016
    Crossref
  10. Study on the impact of smart city construction on the health of the elderly population——A quasi-natural experiment in China, PLOS ONE, 19, 6, (e0305897), (2024).https://doi.org/10.1371/journal.pone.0305897
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share